velphoro
vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - lieky na liečbu hyperkalemia a hyperphosphatemia - velphoro je indikovaná na kontrolu hladiny fosforu v sére dospelých chronickou obličkovou chorobou (ckd) pacientov na hemodialýze (hd) alebo peritoneálnej dialýze (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.
daruph 111 mg
zentiva, k.s., Česká republika - dazatinib - 44 - cytostatica
daruph 79 mg
zentiva, k.s., Česká republika - dazatinib - 44 - cytostatica
daruph 63 mg
zentiva, k.s., Česká republika - dazatinib - 44 - cytostatica
daruph 55 mg
zentiva, k.s., Česká republika - dazatinib - 44 - cytostatica
daruph 40 mg
zentiva, k.s., Česká republika - dazatinib - 44 - cytostatica
daruph 16 mg
zentiva, k.s., Česká republika - dazatinib - 44 - cytostatica
rocaltrol 0,25 µg
roche slovensko - kalcitriol - 86 - vitamina, vitagena
adempas
bayer ag - riociguat - hypertenzia, pľúca - antihypertenzíva pre pľúcnu arteriálnu hypertenziu - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Účinnosť bola preukázaná v pau obyvateľstva vrátane aetiologies z idiopatická alebo dedičné pau alebo pah spojené s spojivového tkaniva ochorenia. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.